An early study using AAV vector-mediated delivery of HSV/TK together with Interleukin 2 in both immunocompetent and immunodeficient murine hepatoma models demonstrated synergistic effects compared to HSV/TK gene transfer alone. This evidence concerns the gene TKT and hepatocellular carcinoma.